Innogen Launches Two Medicines for Hypertension

Hypertension is one of the silent killers in the Philippines today. So the right thing to do is never take it for granted. The killer is called by other names, they are: “High Blood Pressure” and “Arterial Hypertension.” But whatever you call it—it is a killer just the same.

Hypertension is very tricky because in most cases, it does not show clear symptoms and the disease, attacks without warning and usually, it is fatal.

Therefore, when the blood pressure shoots up, don’t waste time but see a doctor right away, so that treatment can be administer promptly to save your life.

Hypertension is also common in obese, diabetic and those who smoke and drink on a regular basis and a lot. The disease normally leads to kidney and heart failure, hardened arteries and impaired visions among other health problems.

To avoid these one should stop smoking and regulate alcoholic drinks and exercise regularly and go for less dietary salt and fat intake.

In line with this, InnoGen Pharma Group now comes into the picture. The company has come up with some cardiovascular and anti-hypertensive pharmaceutical products. Among these products are: Amlodipine, Clopidogrel, Gabapetin and Orlistat.

InnoGen Executive Director Dr. Lloyd D. Balajadia has said: “With this successful undertaking, there is no need to import drugs and medicines from other countries. We can very well manufacture our own. These products are of high quality, with proven efficacy and are safe.”

Having tried generics and proving they are equally safe and effective, physicians and patients have now learned to accept generics.

InnoGen means Innovating Generics. The company thrust is to improve existing pharmaceutical products into new forms that are cost-effective, efficient and of high quality.

Innogen has nine pharmaceutical divisions each of which has specific specialization medical, from women and child care, to hypertension ad cardiovascular therapeutic segments.

InnoGen provides second-to-innovator pharmaceutical products, most of which are off-patent molecules.

It has invested in technology transfer and partnership with big pharmaceutical companies abroad, to avail itself with the latest technologies in the industry.